Literature DB >> 1858864

Nerve blood flow in early experimental diabetes in rats: relation to conduction deficits.

N E Cameron1, M A Cotter, P A Low.   

Abstract

A reduction in nerve blood flow in chronic experimental diabetes has been linked to impaired conduction. Recently, there have been reports that this is preceded by a period of functional hyperemia. The present investigation explored early changes in sciatic nerve endoneurial blood flow and function in streptozocin-treated rats with durations of diabetes from 1 wk to 4 mo. Blood flow was monitored by microelectrode polarography and hydrogen clearance in thiobutabarbital (Inactin)-anesthetized animals. It was reduced by 41% as early as 1 wk after diabetes induction. There was no evidence of an early functional hyperemia, flow remaining 44% depressed up to 4 mo. In another investigation, similar reductions in blood flow were acutely induced in normal rats rendered hyperglycemic by glucose infusion. In diabetic animals, conduction velocity in sciatic branches supplying gastrocnemius and tibialis anterior muscles was correlated with blood flow. The link was further tested using a group of 2-mo diabetic rats treated with guanethidine. Treatment caused a functional adrenergic sympathectomy, and blood flow increased to within the normal range. Conduction velocity, depressed by 26% with diabetes, was normalized by treatment. These observations support the hypothesis that hyperglycemia-induced blood flow reductions and resultant endoneurial hypoxia are important factors underlying nerve conduction deficits early in the development of diabetic neuropathy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1858864     DOI: 10.1152/ajpendo.1991.261.1.E1

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  75 in total

1.  Reversal of experimental diabetic neuropathy by VEGF gene transfer.

Authors:  P Schratzberger; D H Walter; K Rittig; F H Bahlmann; R Pola; C Curry; M Silver; J G Krainin; D H Weinberg; A H Ropper; J M Isner
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

2.  Can VEGF reverse diabetic neuropathy in human subjects?

Authors:  A Veves; G L King
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

3.  Diabetic Neuropathies.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-01       Impact factor: 3.598

4.  Diet-induced obesity in Sprague-Dawley rats causes microvascular and neural dysfunction.

Authors:  Eric P Davidson; Lawrence J Coppey; Nigel A Calcutt; Christine L Oltman; Mark A Yorek
Journal:  Diabetes Metab Res Rev       Date:  2010-05       Impact factor: 4.876

Review 5.  Role of endothelin in diabetic vascular complications.

Authors:  H C Lam
Journal:  Endocrine       Date:  2001-04       Impact factor: 3.633

Review 6.  Early diabetic neuropathy: triggers and mechanisms.

Authors:  Maxim Dobretsov; Dmitry Romanovsky; Joseph R Stimers
Journal:  World J Gastroenterol       Date:  2007-01-14       Impact factor: 5.742

7.  Prevention and reversal of motor and sensory peripheral nerve conduction abnormalities in streptozotocin-diabetic rats by the prostacyclin analogue iloprost.

Authors:  M A Cotter; K C Dines; N E Cameron
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-05       Impact factor: 3.000

Review 8.  Vascular factors in diabetic neuropathy.

Authors:  S Tesfaye; R Malik; J D Ward
Journal:  Diabetologia       Date:  1994-09       Impact factor: 10.122

9.  Impaired blood flow and arterio-venous shunting in human diabetic neuropathy: a novel technique of nerve photography and fluorescein angiography.

Authors:  S Tesfaye; N Harris; J J Jakubowski; C Mody; R M Wilson; I G Rennie; J D Ward
Journal:  Diabetologia       Date:  1993-12       Impact factor: 10.122

10.  Angiotensin II receptor blockade improves nerve function, modulates nerve blood flow and stimulates endoneurial angiogenesis in streptozotocin-diabetic rats and nerve function.

Authors:  E K Maxfield; N E Cameron; M A Cotter; K C Dines
Journal:  Diabetologia       Date:  1993-12       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.